Your browser doesn't support javascript.
loading
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella, David; Grünwald, Viktor; Escudier, Bernard; Hammers, Hans J; George, Saby; Nathan, Paul; Grimm, Marc-Oliver; Rini, Brian I; Doan, Justin; Ivanescu, Cristina; Paty, Jean; Mekan, Sabeen; Motzer, Robert J.
  • Cella D; Northwestern University, Chicago, IL, USA. Electronic address: d-cella@northwestern.edu.
  • Grünwald V; Hannover Medical School, Hannover, Lower Saxony, Germany.
  • Escudier B; Institut Gustave Roussy, Villejuif, France.
  • Hammers HJ; UT Southwestern, Dallas, TX, USA.
  • George S; Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Nathan P; Mount Vernon Cancer Centre, Northwood, London, UK.
  • Grimm MO; Department of Urology, Jena University Hospital, Jena, Germany.
  • Rini BI; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
  • Doan J; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Ivanescu C; IQVIA, Durham, NC, USA.
  • Paty J; IQVIA, Durham, NC, USA.
  • Mekan S; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lancet Oncol ; 20(2): 297-310, 2019 02.
Article en En | MEDLINE | ID: mdl-30658932

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Medición de Resultados Informados por el Paciente / Ipilimumab / Sunitinib / Nivolumab / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Medición de Resultados Informados por el Paciente / Ipilimumab / Sunitinib / Nivolumab / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article